摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Cephalotaxin a u. b | 24316-19-6

中文名称
——
中文别名
——
英文名称
Cephalotaxin a u. b
英文别名
Cephalotoxin;(3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-ol;cephalotaxine;(2S,3S)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-ol
Cephalotaxin a u. b化学式
CAS
24316-19-6;38848-21-4;39707-72-7;61664-33-3
化学式
C18H21NO4
mdl
——
分子量
315.369
InChiKey
YMNCVRSYJBNGLD-OWZOALSMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    131-132 °C(Solv: benzene (71-43-2))
  • 沸点:
    495.2±45.0 °C(Predicted)
  • 密度:
    1.38±0.1 g/cm3(Predicted)
  • 溶解度:
    DMF:10mg/mL;二甲基亚砜:12mg/mL;乙醇:5mg/mL

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    23
  • 可旋转键数:
    1
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    51.2
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 危险等级:
    6.1(b)
  • 危险品标志:
    Xn
  • 安全说明:
    S36
  • 危险类别码:
    R20/21/22
  • WGK Germany:
    3
  • 危险品运输编号:
    UN 1544 6
  • 包装等级:
    III
  • 危险类别:
    6.1(b)

SDS

SDS:c41f9369bf0004f630c6fc09d19cfe05
查看

制备方法与用途

植物提取物

三尖杉碱天然存在于粗榧科三尖杉属植物的茎中,属于生物碱的一种,具有抗癌作用,特别是对慢性血癌疗效显著。三尖杉Cephalotaxus fortunei Hook.f.为我国特产,分布于长江以南及湖北、四川、陕西、甘肃等地。三尖杉果实民间用作消积、驱虫药。

三尖杉酯碱类化合物

目前被大家熟知的三尖杉酯碱类化合物有四种:三尖杉酯碱(Harringtonine)、异三尖杉酯碱(Isoharringtonine)、高三尖杉酯碱(Homoharringtonine)和脱氧三尖杉酯碱(Deoxy harringtonine)。近年还从安徽产三尖杉中分出两种新的抗癌生物碱,分别命名为新三尖杉酯碱(Neoharringtonine)和脱三尖杉酯碱(Anhydroharringtonine)。

  1. 三尖杉酯碱:异名哈林通碱粗榧碱。分子式C28H37NO9,分子量531.58。无色柱状结晶(乙醚),熔点73℃~75℃,[α]D-104.6°(C=1.0,氯仿)。

  2. 高三尖杉酯碱:异名高粗榧碱、高哈林通碱。分子式C29H39NO9,分子量545.61。无色棱柱状结晶,熔点144℃~146℃,[α]D-119°(C=0.96,氯仿)。

  3. 异三尖杉酯碱:异名异粗榧碱、异哈林通碱。分子式 ,分子量531.58。白色无定形固体,[α]D-93°(C=0.41,氯仿)。

  4. 脱氧三尖杉酯碱:异名去氧哈林通碱,分子式C28H37NO8,分子量515.58。无定形固体,[α]D26-151°(C=0.03,乙醇)。

理化性质

三尖杉碱能使四氯化碳溶液退色,并遇浓硫酸出现红色到深紫色的颜色变化,用稀释后颜色变绿。

提取分离
  1. 中国粗榧(Cephalotaxus sinensis)中三尖杉总碱的提取与分离

  2. 应用高速逆流层析(HSCCC)仪分离三尖杉总碱的主要成分
    采用89-A型高速逆流层析仪,以氯仿/0.07mol/L磷酸钠-0.04mol/L柠檬酸缓冲液 (pH5.0) 溶剂系统,上相为固定相,下相为流动相。分离条件为主机正向转动750r/min,流动相从柱内端泵入。将三尖杉总碱10mg溶于流动相1mL进样,UV284nm检测。三尖杉中三个主成分的移动速度依次为:异三尖杉酯碱 > 高三尖杉酯碱 > 三尖杉酯碱。此方法分离效果好,可使以上三种成分完全分离,这是吸附层析难以达到的效果;此外,所用溶剂系统简单,又节约时间,因此优于经典逆流分配法。

生物活性

Cephalotaxlen ((-)-Cephalotaxine) 是一种生物碱,能从头孢紫杉中分离得到,具有抗白血病和抗病毒活性。Cephalotaxlen 具有抗 Zika 病毒的活性。

靶点
  • ZIKV
体外研究
  • Cephalotaxine 抑制 Zika 感染,通过阻碍病毒复制和稳定进行。
用途

用于含量测定、鉴定及药理实验等。

文献信息

  • PROCESS FOR PREPARING CEPHALOTAXINE ESTERS
    申请人:Robin Jean-Pierre
    公开号:US20120022250A1
    公开(公告)日:2012-01-26
    A process for preparing cephalotaxine esters corresponding to the following general formula I which comprises the cephalotaxine backbone: C(R 1 )(R 2 )(XH)COO[CTX] wherein CTX represents the cephalotaxine backbone, being optionally substituted and/or dehydrogenated, in which formula I, X is a heteroatom, preferably an oxygen, a sulfur or a nitrogen, R 1 and R 2 , taken separately, may be alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, heterocycloalkyl or aralkyl groups, said groups being optionally interrupted by ester functions, or groups that can form one or more rings or a heterocycle together, consisting in bringing the corresponding cephalotaxine compound, or salts, isomers or tautomeric forms thereof, which is free or which is in the form of a metal alkoxide corresponding to the following general formula CTXOM, wherein CTX represents the cephalotaxine backbone, being optionally substituted and/or dehydrogenated, in which M is a hydrogen atom or a metal atom, into contact with a heterocyclic side chain precursor having both a bifunctional protected (bidentate) and activated (acylating) form of an acid bearing a hydrogenated heteroatom, in the alpha (α) position with respect to the carboxyl group, and corresponding to the following general formula: in which case W is a carbon, sulfur, silicon or bore atom, X, R 1 and R 2 have respectively the same meaning as above, it being possible for R 1 and R 2 to form a ring or a heterocycle together, and Y and Z are alkyl or heteroalkyl radicals, or monovalent heteroatoms, which may be identical or different, in an independent manner, or may fuse so as to give a divalent heteroatom, it being possible for the X—W bond to be covalent or ionic.
    一种制备对应以下一般式I的头叶松碱酯的方法,其中包括头叶松碱骨架:C(R1)(R2)(XH)COO[CTX],其中CTX代表头叶松碱骨架,可以是可选择地取代和/或脱氢的,在该式I中,X是一个杂原子,优选为氧、或氮,R1和R2,分别取,可以是烷基、环烷基、杂基、芳基、杂芳基、杂环烷基或芳基,这些基团可以通过酯功能团中断,或者可以形成一个或多个环或一个杂环,包括将相应的头叶松碱化合物,或其盐、异构体或互变异构体形式,该化合物是自由的或以属烷氧基的形式存在,对应以下一般式CTXOM,其中CTX代表头叶松碱骨架,可以是可选择地取代和/或脱氢的,在该式中,M是氢原子或属原子,与具有双功能保护(双齿)和活化(酰化)形式的酸的α位上带有氢杂原子的杂环侧链前体接触,该酸与羧基相对应,并对应以下一般式:在这种情况下,W是碳、原子,X、R1和R2分别具有与上述相同的含义,R1和R2可以共同形成一个环或一个杂环,Y和Z是烷基或杂基基,或一价杂原子,可以独立地相同或不同,或者可以融合以形成二价杂原子,X—W键可以是共价键或离子键。
  • ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS
    申请人:Oregon State University
    公开号:US20220009944A1
    公开(公告)日:2022-01-13
    Disclosed herein are embodiments of a compound having a Formula I or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. Also disclosed are derivative compounds made from the compound of Formula I. Certain derivative compounds have a Formula V-2, or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. Also disclosed are method for making and using the disclosed compounds. Certain disclosed embodiments are useful for treating and/or preventing certain diseases and/or disorders, including proliferation diseases, such as leukemia.
查看更多

同类化合物

高三尖杉酯碱酰胺 高三尖杉酯碱 氧桥三尖杉碱 异三尖杉酯碱 双(去甲基)-脱氧三尖杉酯碱 去甲基三尖杉酮碱 去氧哈林通碱 乙酰三尖杉碱 三尖杉酯碱 三尖杉酯碱 三尖杉碱 4-羟基三尖杉碱 4'-去甲基高三尖杉酯碱 (1S,3aR)-1,5,6,8,9,14bbeta-六氢-2-甲氧基-4H-环戊并[a][1,3]二氧杂环戊并[4,5-H]吡咯并[2,1-b][3]苯并氮杂卓-1alpha,9alpha-二醇 (-)-脱水三尖杉酯碱 (2S,3R,4S,5S,7R)-2,3-dihydroxy-7-methyl-cephalotaxan-8-one (2R,3S,4S,5S)-2,3-dihydroxy-8-oxocephalotaxane (+/-)-D-homocephalotaxine Desmethyldiacetyl-cephalotaxin (3aα,4S*,10β,15bβ,15cα)-(+/-)-10-acetoxy-3a,4,6,7,9,10,15b,15c-octahydro-2,2-dimethyl-5H-<1,3>dioxolo<4,5-h>-1,3-dioxolo<4,5>cyclopenta<1,2-a>pyrrolo<2,1-b><3>benzazepine Cephalotaxyl 6,6-dimethyl-5,6-dihydropyran-1-carboxylate 3t-phenyl-acrylic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester 6-O-(4-methylimidazole-3-carbonyl)2,6-diacetylhomoharringtonine 6-O-(2-chloropyridin-3-carbonyl)2,6-diacetylhomoharringtonine (Ξ)-methylsuccinic acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester 6-O-(phenylacetyl)2,6-diacetylhomoharringtonine 6-O-(furan-2-carbonyl)2,6-diacetylhomoharringtonine succinic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester methyl ester O-3-[(2R)-2,6-dihydroxy-2-(2'-cyclohexaneamino-2'-oxoethyl)-6-methylheptanoyl]cephalotaxine (2R,7R)-17,19-dioxa-11-azapentacyclo[12.7.0.02,7.07,11.016,20]henicosa-1(21),4,12,14,16(20)-pentaen-10-one Acetic acid 6-((1aR,2aS,5aR,6S,6aS)-5-methyl-4-oxo-octahydro-1-oxa-5-aza-cyclopropa[f]inden-6-yl)-benzo[1,3]dioxol-5-ylmethyl ester (Ξ)-(3-methyl-butyl)-succinic acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester 1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-[4-methyl-4-(4-methyl-1,3-thiazole-5-carbonyl)oxypentyl]-2-(4-methyl-1,3-thiazole-5-carbonyl)oxybutanedioate 3,8-dioxocephalotax-1-ene furan-3,4-dicarboxylic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester methyl ester 2α,3α-dihydroxycephalotaxan-8-one 2,3-dehydrocephalotaxan-8-one 1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-[4-(cyclohexanecarbonyloxy)-4-methylpentyl]-2-hydroxybutanedioate 2α,3α-epoxycephalotaxan-8-one [(2S,3R,4S,6S)-3-acetyloxy-9-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-4-yl] acetate (3-methyl-butyl)-butenedioic acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester benzyl ((2S,3S,3aR)-2,3-dihydroxy-2,3,5,6,8,9-hexahydro-4H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]cyclopenta[b]pyrrolo[1,2-a]azepin-1-yl) carbonate 3t-(4-nitro-phenyl)-acrylic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (2R,3S,4S,5S)-2-(tert-butyldimethylsililoxy)-3-hydroxy-8-oxocephalotaxane